Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| enzymes | 5021 | None |
| Molecule | Description |
|---|---|
|
Synonyms:
|
genetically engineered, glycosylated human alpha-galactosidase isoenzyme A used in treatment of Fabry disease
|
| Dose | Unit | Route |
|---|---|---|
| 1 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 3, 2001 | EMA |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Inappropriate schedule of product administration | 34.62 | 31.78 | 20 | 834 | 149913 | 90477680 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Poor venous access | 40.72 | 37.30 | 10 | 366 | 7242 | 42613717 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Poor venous access | 54.77 | 32.10 | 18 | 1441 | 24504 | 110563336 |
| Inappropriate schedule of product administration | 47.78 | 32.10 | 31 | 1428 | 203606 | 110384234 |
| Blood pressure decreased | 38.48 | 32.10 | 22 | 1437 | 115069 | 110472771 |
None
| Source | Code | Description |
|---|---|---|
| ATC | A16AB03 | ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Enzymes |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Fabry's disease | indication | 16652001 | DOID:14499 |
None
None
None
None
None
None
| ID | Source |
|---|---|
| D02784 | KEGG_DRUG |
| 104138-64-9 | SECONDARY_CAS_RN |
| CHEBI:753217 | CHEBI |
| CHEMBL2108214 | ChEMBL_ID |
| C000627036 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB15874 | DRUGBANK_ID |
| 2691830 | RXNORM |
| 008578 | NDDF |
| 423634009 | SNOMEDCT_US |
| 424905009 | SNOMEDCT_US |
| C0962517 | UMLSCUI |
| 8048 | INN_ID |
| 52918379 | PUBCHEM_CID |
| 2HLC17MX9G | UNII |
None